Takeda Says Failed Norovirus Vaccine Study Supports Further Work
This article was originally published in The Pink Sheet Daily
Norovirus vaccine missed primary endpoint in Phase I/II study highlighted at IDWeek, but did show activity in minimizing severity of infection. With tens of millions of cases every year in the U.S., the market would be large.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.